Sonoma Pharmaceuticals, Inc. — Form 8-K

On October 6, 2026, Sonoma Pharmaceuticals amended and restated its Section 382 Rights Agreement (originally dated October 18, 2016, expiring October 18, 2026). The new agreement runs through October 6, 2036 and creates Series B Preferred Stock (100,000 authorized shares, none issued) with voting power of 1,000x per share. One Right attaches to each common share; Rights become exercisable if any person/group acquires 4.99%+ beneficial ownership (an 'Acquiring Person'). Upon trigger, each Right entitles holder to purchase 1/1,000th Preferred Share at $10.00, or (post-trigger) receive Common Shares worth 2x the $10 Purchase Price. Rights held by Acquiring Persons become null and void. Computershare Inc. appointed Rights Agent.